Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment
ConclusionsOur results indicate that PEITC targets HER2-positive CSCs and that its combination with trastuzumab may pave the way for a novel therapeutic strategy for HER2-positive tumors.
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Herceptin | MRI Scan | Ovarian Cancer | Ovaries | Stem Cell Therapy | Stem Cells